|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
70,932,000 |
Market
Cap: |
2.94(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$15.81 - $52.44 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on changing the paradigm for the treatment of rare genetic diseases of obesity, which are characterized by early-onset, severe obesity and hyperphagia, a pathological and insatiable hunger. Co. is developing IMCIVREE (setmelanotide) as a medicine strategy for a subset of individuals who have severe obesity due to genetic variants that impair the melanocortin-4 receptor pathway, a pathway in the brain that is responsible for regulating hunger, caloric intake and energy expenditure, which consequently affect body weight.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
22,587 |
269,851 |
390,685 |
429,469 |
Total Sell Value |
$904,227 |
$11,716,886 |
$15,609,906 |
$16,448,857 |
Total People Sold |
2 |
7 |
7 |
8 |
Total Sell Transactions |
3 |
29 |
42 |
61 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Desikan Nithya |
Chief Commercial Officer |
|
2019-12-27 |
4 |
OE |
$6.88 |
$242,045 |
D/D |
35,181 |
64,249 |
|
- |
|
Foley Todd |
Director |
|
2019-12-12 |
4 |
AS |
$25.01 |
$94,088 |
I/I |
(3,762) |
2,393,497 |
|
- |
|
Foley Todd |
Director |
|
2019-12-11 |
4 |
AS |
$25.14 |
$341,904 |
I/I |
(13,600) |
2,397,259 |
|
- |
|
Foley Todd |
Director |
|
2019-12-10 |
4 |
AS |
$25.36 |
$1,061,037 |
I/I |
(41,839) |
2,410,859 |
|
- |
|
Foley Todd |
Director |
|
2019-12-09 |
4 |
AS |
$25.04 |
$555,763 |
I/I |
(22,195) |
2,452,698 |
|
- |
|
Foley Todd |
Director |
|
2019-12-03 |
4 |
AS |
$22.33 |
$374,630 |
I/I |
(16,777) |
2,474,893 |
|
- |
|
Foley Todd |
Director |
|
2019-12-02 |
4 |
AS |
$22.03 |
$558,813 |
I/I |
(25,366) |
2,491,670 |
|
- |
|
Foley Todd |
Director |
|
2019-11-25 |
4 |
AS |
$23.04 |
$2,810,839 |
I/I |
(121,343) |
2,644,580 |
|
- |
|
Foley Todd |
Director |
|
2019-11-22 |
4 |
AS |
$21.78 |
$2,236,718 |
I/I |
(102,682) |
2,765,923 |
|
- |
|
Foley Todd |
Director |
|
2019-11-21 |
4 |
AS |
$20.50 |
$1,334,141 |
I/I |
(64,923) |
2,868,605 |
|
- |
|
Foley Todd |
Director |
|
2019-11-20 |
4 |
AS |
$22.02 |
$3,112,857 |
I/I |
(141,365) |
2,933,528 |
|
- |
|
Kolchinsky Peter |
10% Owner |
|
2019-10-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,422,312 |
|
- |
|
Desikan Nithya |
Chief Commercial Officer |
|
2019-08-12 |
4 |
OE |
$6.88 |
$99,994 |
D/D |
14,534 |
29,068 |
|
- |
|
Gottesdiener Keith Michael |
CEO and President |
|
2019-07-16 |
4 |
OE |
$4.59 |
$34,425 |
D/D |
7,500 |
513,842 |
|
- |
|
Smith Hunter C |
Chief Financial Officer |
|
2019-07-11 |
4 |
OE |
$6.88 |
$68,800 |
D/D |
10,000 |
16,000 |
|
- |
|
Van Der Ploeg Leonardus H.t. |
Chief Scientific Officer |
|
2019-05-31 |
4 |
S |
$25.10 |
$125,500 |
D/D |
(5,000) |
42,339 |
|
- |
|
Van Der Ploeg Leonardus H.t. |
Chief Scientific Officer |
|
2019-05-31 |
4 |
OE |
$4.59 |
$22,950 |
D/D |
5,000 |
47,339 |
|
- |
|
Van Der Ploeg Leonardus H.t. |
Chief Scientific Officer |
|
2019-05-30 |
4 |
S |
$25.31 |
$126,550 |
D/D |
(5,000) |
42,339 |
|
- |
|
Van Der Ploeg Leonardus H.t. |
Chief Scientific Officer |
|
2019-05-30 |
4 |
OE |
$4.59 |
$22,950 |
D/D |
5,000 |
47,339 |
|
- |
|
Van Der Ploeg Leonardus H.t. |
Chief Scientific Officer |
|
2019-05-29 |
4 |
S |
$25.51 |
$127,550 |
D/D |
(5,000) |
42,339 |
|
- |
|
Van Der Ploeg Leonardus H.t. |
Chief Scientific Officer |
|
2019-05-29 |
4 |
OE |
$4.59 |
$22,950 |
D/D |
5,000 |
47,339 |
|
- |
|
Van Der Ploeg Leonardus H.t. |
Chief Scientific Officer |
|
2019-05-28 |
4 |
S |
$25.38 |
$253,800 |
D/D |
(10,000) |
42,339 |
|
- |
|
Van Der Ploeg Leonardus H.t. |
Chief Scientific Officer |
|
2019-05-28 |
4 |
OE |
$4.59 |
$46,117 |
D/D |
10,000 |
52,339 |
|
- |
|
Gottesdiener Keith Michael |
CEO & President |
|
2019-03-18 |
4 |
AS |
$30.27 |
$70,499 |
D/D |
(2,329) |
506,342 |
|
- |
|
Gottesdiener Keith Michael |
CEO & President |
|
2019-03-15 |
4 |
AS |
$30.04 |
$239,148 |
D/D |
(7,961) |
508,671 |
|
- |
|
253 Records found
|
|
Page 8 of 11 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|